SIG
58
-2
DG
33
2
EFX
60
-3
HOG
48
3
MKC
62
3
APH
64
-6
PCAR
33
2
BBY
46
10
VTR
58
4
ABT
62
2
UPS
25
2
OMC
57
2
AN
40
-6
PEP
51
7
SRE
45
7
WM
76
3
CAG
55
7
ESS
50
2
CRM
35
-7
EQT
57
-5
SIG
58
-2
DG
33
2
EFX
60
-3
HOG
48
3
MKC
62
3
APH
64
-6
PCAR
33
2
BBY
46
10
VTR
58
4
ABT
62
2
UPS
25
2
OMC
57
2
AN
40
-6
PEP
51
7
SRE
45
7
WM
76
3
CAG
55
7
ESS
50
2
CRM
35
-7
EQT
57
-5
Financhill
Back

Viridian Therapeutics 10K Form

Sell
1

VRDN
Viridian Therapeutics

Last Price:
$14.68
Seasonality Move:
5.75%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive VRDN News And Ratings

See the #1 stock for the next 7 days that we like better than VRDN

VRDN Financial Statistics

Sales & Book Value

Annual Sales: $302K
Cash Flow: $-73.4M
Price / Cash Flow: 0
Annual Sales: $5.96
Price / Book: 2.39

Profitability

EPS (TTM): -3.77000
Net Income (TTM): $-269.9M
Gross Margin: $789K
Return on Equity: -46.02%
Return on Assets: -41.91%

Viridian Therapeutics Earnings Forecast

Key Viridian Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 5 years for VRDN is 23.64%.
  • The Selling, General & Administrative Expenses for VRDN have been equal to 20,226.16% of Gross Profit Margin.
  • The Research & Development expenses have been 78,892.05% of Revenue.
  • The Net Earning history of VRDN is -89,387.09% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 8 years.

Viridian Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: VRDN
Website: viridiantherapeutics.com

Debt

Debt-to-Equity Ratio: 0.03
Current Ratio: 15.43
Quick Ratio: 14.99

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

VRDN Technical Analysis vs Fundamental Analysis

Sell
1
Viridian Therapeutics (VRDN) is a Sell

Is Viridian Therapeutics a Buy or a Sell?